Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
54.8M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
34.6M
-
Shares change
-
-266K
-
Total reported value, excl. options
-
$324M
-
Value change
-
-$1.75M
-
Put/Call ratio
-
0.69
-
Number of buys
-
78
-
Number of sells
-
-67
-
Price
-
$9.36
Significant Holders of Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) as of Q3 2022
183 filings reported holding CARA - Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2022.
Cara Therapeutics, Inc. - Common Stock, par value $0.001 per share (CARA) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.6M shares
of 54.8M outstanding shares and own 63.08% of the company stock.
Largest 10 shareholders include BlackRock Inc. (7.58M shares), VANGUARD GROUP INC (3.31M shares), Bain Capital Life Sciences Investors, LLC (2.65M shares), FARALLON CAPITAL MANAGEMENT LLC (2.5M shares), STATE STREET CORP (1.88M shares), DISCIPLINED GROWTH INVESTORS INC /MN (1.7M shares), KINGDON CAPITAL MANAGEMENT, L.L.C. (1.33M shares), Chescapmanager LLC (1.16M shares), DIMENSIONAL FUND ADVISORS LP (1.01M shares), and GEODE CAPITAL MANAGEMENT, LLC (820K shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.